This approach shows promise in potentially curtailing NF‐κB activity, regulating cytokine storms, and addressing the onset of ARDS among individuals diagnosed with COVID‐19 pneumonia.17 The gene discussed is NFKB1; the disease is acute respiratory distress syndrome.